Document Generated: 2023-10-01

1

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision of 4 April 2012 amending Decision 2001/861/EC as regards novaluron (notified under document C(2012) 2164) (Text with EEA relevance) (2012/187/EU). (See end of Document for details)

## **ANNEX**

ANNEX ACTIVE SUBSTANCES CONCERNED BY THIS DECISIONNoCommon Name, CIPAC Identification NumberNotifierDate of applicationRapporteur Member State1LaminarinCIPAC No 671Laboratoires Goëmar SA, France29 March 2001Belgium

Document Generated: 2023-10-01

## **Status:**

Point in time view as at 31/01/2020.

## **Changes to legislation:**

There are currently no known outstanding effects for the Commission Implementing Decision of 4 April 2012 amending Decision 2001/861/EC as regards novaluron (notified under document C(2012) 2164) (Text with EEA relevance) (2012/187/EU).